Genio

Dr. Justin Wiseman is the CEO of MS Pen Technologies, Inc. and Genio Technologies, Inc. Justin is a high-tech entrepreneur and inventor and is the former Chairman, President & CEO of Prosolia, Inc., an analytical instrument company specializing in innovative mass spectrometry solutions for life sciences. During his tenure as CEO of Prosolia from 2010-2019, he oversaw the commercialization of proprietary mass spectrometry imaging technology and its expansion from research into clinical and applied markets through its acquisition by Waters Corporation. Justin received a B.S. in chemistry from the University of Indianapolis and a Ph.D. in Analytical Chemistry from Purdue University. While at Purdue, he completed the Applied Management Principles Executive Education program at Krannert School of Management and was the recipient of Schering Plough's Science and Innovation Award for his work on the invention of DESI mass spectrometry. In 2019, he was named Distinguished Outstanding Alumni Entrepreneur by the College of Science at Purdue University.

B.S. in Chemistry, University of Indianapolis
Ph.D. in Analytical Chemistry, Purdue University
Applied Management Principles Executive Education Program, Krannert School of Management

Dr. Eberlin is a Co-Founder and Chief Scientific Officer of Genio Technologies, Inc. and an Assistant Professor in the Departments of Chemistry, Oncology, and Diagnostic Medicine at the University of Texas at Austin, and an adjunct Assistant Professor in the Department of Surgery at Baylor College of Medicine.  Dr. Eberlin is passionate about research at the intersection of chemistry and medicine. She has focused her career on developing innovative mass spectrometry technologies to address critical problems in healthcare. 

Dr. Eberlin received her B.S. in Chemistry from the State University of Campinas, her Ph.D. in Analytical Chemistry from Purdue University, and pursued her postdoctoral research in the Department of Chemistry at Stanford University. In 2016, Dr. Eberlin started her independent career as an assistant professor at The University of Texas at Austin. Eberlin is the recipient of many honors and awards for her scientific research, including an NIH Pathway to Independence Award, Forbes 30 under 30 listing in the Healthcare category, a Moore Inventor Fellowship, and most notably a MacArthur “Genius” Fellowship in 2018. Her research program centers around the development and application of novel mass spectrometry technologies in health-related research, with a particular focus on disease detection and diagnosis to improve patient care and clinical outcomes. Dr. Eberlin has published more than 65 research articles in top-rated journals such as PNAS, Science Translational Medicine, Nature Communications, Cancer Research, and Clinical Chemistry.

She is passionate about the representation of women and diversity in science and is an outspoken advocate for promoting women in higher levels of academia as well as leadership.

Ph.D., Purdue University

B.S., Universidade Estadual de Campinas

Dr. Suliburk is a Co-Founder and Chief Medical Officer of Genio Technologies, Inc.  He is a board-certified surgeon specializing in the treatment of tumors of the thyroid, parathyroid, and adrenal gland. As a fellowship-trained endocrine surgeon, he specializes in the care of patients with thyroid nodules, goiter, Graves’ disease, thyroid cancer, hyperparathyroidism, adrenal masses, pheochromocytoma, Cushing’s, and Conn’s diseases. His advanced surgical expertise includes minimally invasive parathyroidectomy and thyroidectomy, traditional open thyroidectomy, central, selective, and modified radical neck dissection, single incision laparoscopic adrenalectomy, and traditional laparoscopic adrenalectomy.
 Dr. Suliburk researches clinical outcomes in endocrine surgery in underserved and minority populations, outcomes in acute care and trauma surgery, the application of mobile technology to improve perioperative surgical care, and communication with patients to detect impending complications. His research program at Ben Taub Hospital and Baylor St. Luke’s CHI Medical Center offers opportunities in translational science, clinical outcomes, and mobile technology development/innovation.  

MD, University of Oklahoma College of Medicine

B.S., University of Oklahoma 

Dr. Milner is a Co-Founder and Technology Advisor for Genio Technologies, Inc.  Dr. Milner is a prolific innovator who has secured 55 U.S. patents and five international patents, licensed to six companies. Dr. Milner has pioneered multiple technologies for surgical and diagnostic purposes, contributing greatly to many medical disciplines.  Dr. Milner is also co-founder of CardioSpectra and Dermalucent.  His patent royalties to university IP Owners/Licensees have returned over $100 million in revenue, and he has authored 190 peer-reviewed articles and eight book chapters. 

Ph.D., University of Arizona

M.S., Colorado School of Mines

B.S., Colorado School of Mines